West Pharmaceutical Services has announced an agreement with Janssen Biotech, a biotechnology company to partner on the development and manufacturing of a new self-injection product developed by Janssen.
The new injection technology, which will be marketed by West under the name SelfDose, has been specifically designed to address the patient needs by facilitating easier self-injection of pharmaceutical and biologic drug products.
According to West, the SelfDose injection technology helps to meet the challenges pertaining to packaging and delivering sensitive and complex biopharmaceutical products that require a reliable drug container and also a delivery system that can enable safe delivery of the medication.
As part of the agreement, West will co-develop and handle the commercial scale-up and manufacture of the product, and will have the ability to offer the technology as part of its portfolio of self-injection technology platforms.
The SelfDose injection technology offers a solution for enhanced manual injection and matches West's ConfiDose and SmartDose injection technologies.
